Development and validation of a stability-indicating UHPLC–MS/MS method for simultaneous quantification of bupropion, hydroxybupropion, sertraline and desmethylsertraline: application to forced degradation studies
Abstract
Background: Bupropion and sertraline, together with their major metabolites hydroxybupropion and desmethylsertraline, require reliable simultaneous determination for pharmaceutical quality control, stability assessment, and analytical characterization. Methodology: A rapid UHPLC–ESI–MS/MS method was developed using an Acquity UPLC BEH C18 column. The mobile phase consisted of 5 mM ammonium formate in water containing 0.1% formic acid and acetonitrile containing 0.1% formic acid. Detection was performed by multiple reaction monitoring in positive electrospray ionization mode. The method was validated for specificity, linearity, accuracy, precision, sensitivity, robustness, and solution stability according to applicable ICH Q2(R2) analytical validation principles. Forced degradation was evaluated under acidic, alkaline, oxidative, thermal, photolytic, and neutral hydrolytic conditions. Results and Discussion: All four target analytes were selectively detected within a 10-min run time, with no significant interfering responses observed at their respective retention times. Oxidative stress produced the greatest loss of intact analyte, whereas thermal and neutral hydrolytic conditions caused comparatively lower degradation. Selective parent-analyte monitoring under stressed conditions supported the applicability of the quantitative method. Conclusion: The validated method is rapid, sensitive, accurate, and suitable for pharmaceutical quality control, assay determination, stability studies, and forced-degradation assessment of the investigated compounds.